Xilio Development, Inc.
Xilio Development, Inc.
Explore linked clinical trials.3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC | Digestive System Diseases, Digestive System Neoplasms, Fanconi anemia complementation group D1, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Not yet recruiting | Phase 2 | 2026-08-14 | NCT07765836 | |
| XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Not yet recruiting | Phase 1 / Phase 2 | 2026-07-07 | NCT07688577 | |
| XTX301 in Patients With Advanced Solid Tumors | Advanced Solid Tumor | Recruiting | Phase 1 / Phase 2 | 2026-06-23 | NCT05684965 |